1. Daly JM, Kemeny NE. Metastatic cancer to the liver. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: principles & practice of oncology (5th ed). Philadelphia: Lippincott-Raven, 1997: 2551.
2. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999; 49: 8.
3. Gorog D, Toth A, Weltner J. Prognosis of untreated liver metastasis from rectal cancer. Acta Chir Hung 1997; 36: 106.
4. Burke D, Allen-Mersh TG. Colorectal liver metastases. Postgrad Med J 1996; 72: 464.
5. Rougier P, Milan C, Lazorthes F et al. Prospective study of prognostic factors in patients with unresected hepatic metastases from colorectal cancer. Br J Surg 1995; 82: 1397.
6. Palmer M, Petrelli NJ, Herrera L. No treatment option for liver metastases from colorectal adenocarcinoma. Dis Colon Rectum 1989; 32: 698.
7. Petrelli NJ, Bonnheim DC, Herrera LO. A proposed classification system for liver metastases from colorectal carcinoma. Dis Colon Rectum 1984; 27: 249.
8. Sutliff VE, Doppman JL, Gibril F et al. Growth of newly diagnosed, untreated metastatic gastrinomas and predictors of growth patterns. J Clin Oncol 1997; 15: 2420.
9. Lahr CJ, Soong S-J, Cloud G et al. A multifactorial analysis of prognostic factors in patients with liver metastases from colorectal carcinoma. J Clin Oncol 1983; l: 720.
10. Finan PJ, Marshall RJ, Cooper EH, Giles GR. Factors affecting survival in patients presenting with synchronous hepatic metastases from colorectal cancer: a clinical and computer analysis. Br J Surg 1985; 72: 373.
11. Ayoub J-P, Hess KR, Abbruzzese MC et al. Unknown primary tumors metastatic to liver. J Clin Oncol 1998; 16: 2105.
12. Seregard S, Коек Е. Prognostic indicators following enucleation for posteваrior uveal melanoma. Acta Ophthalmol Scand 1995; 73: 340.
13. Ravikumar TS, Buenaventura S, Salem RR, D'Andrea B. Intraoperative ultrasonography of liver: detection of occult liver tumors and treatment by
14. Inoue E, Fujita M, Hosomi N et al. Double phase CT arteriography of the whole liver in the evaluation of hepatic tumors. J Comput Assist Tomogr 1998; 22: 64.
15. Ch'en IY, Katz DS, Jeffrey В Jr et al. Do arterial phase helical CT images improve detection or characterization of colorectal liver metastases? J Comput Assist Tomogr 1997; 21: 391.
16. Niederhuber JE, Ensminger W, Gyves J et al. Regional chemotherapy of colorectal cancer metastatic to the liver. Cancer 1984; 53: 1336.
17. Fordy C, Burke D, Earlam S et al. Treatment interruptions and complications with two continuous hepatic artery floxuridine infusion systems in colorectal liver metastases. Br J Surg 1995; 82: 1023.
18. Kemeny NE, Ron IG. Hepatic arterial chemotherapy in metastatic colorectal patients. Semin Oncol 1999; 26: 524.
19. Burke D, Earlan S, Fordy C, Allen-Mersh TG. Effect of aberrant hepatic arterial anatomy on tumour response to hepatic artery infusion of floxuridine for colorectal liver metastases. Br J Surg 1995; 82: 1098.
20. Sigurdson ER, Ridge JA, Daly JM. Fluorodeoxyuridine uptake by human colorectal hepatic metastases after hepatic artery infusion. Surgery 1986; 100: 285.
21. Campbell KA, Burns RC, Sitzmann JV et al. Regional chemotherapy devices: effect of experience and anatomy on complications. J Clin Oncol 1993; 11: 822.
22. Breedis C, Young G. Blood supply of neoplasms of the liver. Am J Pathol 1954; 30: 969.
23. Dorr RT, Von Hoff DD. Floxuridine. In: Anonymous, Cancer chemotherapy handbook. Norwalk, CT: Appleton & Lange, 1994: 489.
24. Ensminger WD, Rosowsky A, Raso V et al. A clinicalpharmacologic evaluation of hepatic arterial infusions of 5-fluoro-2'-deoxyuridine and 5-fluorouracil. Cancer Res 1978; 38: 3784.
25. Ensminger WD, Walker SC, Stetson PL et al. Clinical pharmacology of hepatic arterial infusions of 5-bromo-2'-deoxyuridine. Cancer Res 1996; 54: 2121.
26. Sigurdson ER, Ridge JA, Kemeny N, Daly JM. Tumor and liver drug uptake following hepatic artery and portal vein infusion in man. J Clin Oncol 1987; 5: 1836.
27. Venook AP. Update on hepatic intra-arterial chemotherapy. Oncology 1997; 11: 947.
28. Kemeny NE. Regional chemotherapy of colorectal cancer. Eur J Cancer 1995; 31A: 1271.
29. Stagg RJ, Venook AP, Chase JL et al. Alternating hepatic intra-arterial floxuridine and fluorouracil: a less toxic regimen for treatment of liver metastases from colorectal cancer. J Natl Cancer Inst 1991; 83: 423.
30. Kemeny N, Seiter K, Conti JA et al. Hepatic arterial floxuridine and leucovorin for unresectable liver metastases from colorectal carcinoma. New dose schedules and survival update. Cancer 1994; 73: 1134.
31. Kemeny N, Conti JA, Cohen A et al. Phase II study of hepatic arterial floxuridine, leucovorin, and dexamethasone for unresectable liver metastases from colorectal carcinoma. J Clin Oncol 1994; 12: 2288.
32. Kemeny N, Daly J, Reichman B et al. Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. Ann Intern Med 1987; 107: 459.